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Active vitamin D compounds repress parathyroid hormone
(PTH) gene transcription and block chief cell hyperplasia,
making them integral tools in the treatment of secondary
hyperparathyroidism in patients with chronic kidney disease.
Recently, human parathyroid glands have been shown to
express 25-hydroxyvitamin D 1a-hydroxylase (1aOHase), but
documentation of the 1aOHase activity in parathyroid cells
and its potential role in activating 25-hydroxyvitamin D3
(25(OH)D3) to 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) have
not been reported. The relative potencies of 25(OH)D3 and
1,25(OH)2D3 in reducing PTH secretion and mRNA were
determined in primary cultures of bovine parathyroid cells
(bPTC). The effects of blocking 1aOHase activity on
suppression of PTH mRNA and induction of 24-hydroxylase
mRNA were examined. Vitamin D receptor (VDR) affinities
were estimated by intact cell competitive binding assay.
Metabolism of 25(OH)D3 by bPTC was assessed using a
radioimmunoassay that measures all 1-hydroxylated
metabolites of vitamin D. 25(OH)D3 suppressed PTH secretion
and mRNA (ED50¼ 2 nM), but was several hundred times less
potent than 1,25(OH)2D3. The lower potency of 25(OH)D3
correlated with its lower VDR affinity. bPTCs converted
25(OH)D3 to 1-hydroxylated metabolites, but the rate of
conversion was low. Inhibition of 1aOHase with the
cytochrome P450 inhibitor clotrimazole did not block
25(OH)D3-mediated suppression of PTH. Clotrimazole
enhanced 24-hydroxylase mRNA induction, presumably by
inhibiting catabolism of 25(OH)D3. In conclusion, 25(OH)D3
suppresses PTH synthesis by parathyroid cells, possibly by
direct activation of the VDR.
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The parathyroid glands are a well-established target tissue
for vitamin D actions. The parathyroid hormone (PTH)-
secreting chief cells contain high levels of the vitamin D
receptor (VDR), and 1,25-dihydroxyvitamin D3 (1,25(OH)2
D3) has been shown to inhibit PTH gene transcription
1–3 and
to block parathyroid cell hyperplasia.4–6 The actions of
vitamin D in the parathyroid glands has led to the
therapeutic application of 1,25(OH)2D3 and its analogs for
the treatment of secondary hyperparathyroidism in patients
with chronic kidney disease.7
Secondary hyperparathyroidism is also prevalent in the
general population and is associated with vitamin D
deficiency.8–11 PTH levels have been shown to be inversely
correlated with the serum levels of 25-hydroxyvitamin D3
(25(OH)D3), the major circulating vitamin D metabolite and
an indicator of vitamin D status.8–12 In subjects with mild
to moderate vitamin D deficiency (25(OH)D3, 8–30 ng/ml),
no correlation was noted between PTH and 1,25(OH)2D3 or
calcium.11,13 Although feedback loops have been proposed to
explain the absence of the latter correlations,14 the possibility
of a direct effect of 25(OH)D3 on PTH cannot be excluded.
The recent report of Segersten et al.15 that 1a-hydroxylase
(1aOHase) mRNA and protein can be detected in human
parathyroid glands suggested a possible autocrine system
in which circulating 25(OH)D3 can be converted to
1,25(OH)2D3 within parathyroid cells. However, it is not
clear if the level of 1aOHase activity in parathyroid glands is
capable of producing sufficient amounts of 1,25(OH)2D3 to
affect PTH secretion. In the present study, we have measured
the rate of 1-hydroxylation of 25(OH)D3, determined the
relative PTH-suppressing potencies and VDR affinities
of 25(OH)D3 and 1,25(OH)2D3, and examined the effects
of blocking conversion to 1,25(OH)2D3 on the efficacy of
25(OH)D3 to regulate parathyroid cell function.
RESULTS
Expression of vitamin D-metabolizing enzymes by bPTC
We confirmed that bovine parathyroid cells (bPTC) in
culture express the 1aOHase as has been reported for human
parathyroid glands. Reverse transcription-PCR produced a
single band of the expected 600 bp that was absent in the no
reverse transcription controls (Figure 1). Sequence analysis
revealed only a single mismatch with the published sequence
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2006 International Society of Nephrology
Received 1 November 2005; revised 4 January 2006; accepted 31
January 2006; published online 28 June 2006
Correspondence: AJ Brown, Renal Division, Washington University School
of Medicine, Box 8126, 660 S Euclid, St Louis, Missouri 63110, USA.
E-mail: abrown@im.wustl.edu
654 Kidney International (2006) 70, 654–659
of a putative bovine 1aOHase clone assembled from the
bovine genomic sequence (accession no. XM 588481).
Metabolism of 25(OH)D3 by bPTC
Previous studies by our laboratory were unable to detect the
production of 1,25(OH)2D3 by bPTC using high-pressure
liquid chromatography to resolve the metabolites and a
radioreceptor assay to quantify the 1,25(OH)2D3 peak
(unpublished results). One explanation for this could be
the rapid conversion of the 1,25(OH)2D3 to more polar
metabolites by the high 24-hydroxylase activity in bPTC.16 To
circumvent the limitation of the previous approach, we used
a radioimmunoassay (RIA) that recognizes the 1a-hydroxyl
group. Figure 2 shows that 1-hydroxylated metabolites of
25(OH)D3 could be detected when parathyroid cells were
incubated with concentrations of 25(OH)D3 above 10 nM.
However, the 1aOHase activity was low, and total 1-hydroxy-
lated metabolites accumulating in the medium over a
24-h period was less than 1% of the input substrate (100
or 1000 nM). The antibodies used in this assay recognize the
1-hydroxyl group and should detect all 1-hydroxylated
metabolites, including calcitroic acid, the end product of
1,25(OH)2D3 metabolism by the 24-hydroxylase. At present,
the efficiency of detecting the metabolites of 1,25(OH)2D3
compared to 1,25(OH)2D3 itself has not yet been rigorously
determined for this assay. Thus, the values must be tenta-
tively viewed as approximate rates of enzyme activity.
Nonetheless, the assay provides a more accurate assessment
of activity than simply measuring the transient levels of
1,25(OH)2D3 in the cultures, and provides a means for
monitoring the inhibition of metabolism in subsequent
experiments.
Suppression of PTH secretion and mRNA by 25(OH)D3
Active vitamin D compounds repress PTH gene transcription
in a VDR-dependent manner leading to a reduction in the
steady-state rate of PTH release. The relative effects of
25(OH)D3 and 1,25(OH)2D3 on PTH secretion by bPTC are
shown in Figure 3. In this assay, 25(OH)D3 was several
hundred times less active than 1,25(OH)2D3. Similar results
were obtained when PTH mRNA was measured as the end
point (Figure 4).
Role of 1-hydroxylation in suppression of PTH by 25(OH)D3
The effective concentration of 25(OH)D3 for suppression
of PTH (410 nM) was similar to that required for effective
1-hydroxylation (Figures 2 and 3). To determine if conversion
to 1,25(OH)2D3 was required for the biological action
of 25(OH)D3 in bPTC, the activity of the 1aOHase was
inhibited using the general cytochrome P450 inhibitor
clotrimazole. As shown in Figure 5, 1-hydroxylation of
25(OH)D3 (100 nM) was completely blocked by clotrimazole
at concentrations above 0.3 mM. Surprisingly, we found that
inhibition of the 1aOHase in bPTC did not prevent
the reduction of PTH mRNA by 100 nM 25(OH)D3 (Figure 6).
In fact, clotrimazole potentiated the induction of 24-OHase
mRNA by 25(OH)D3 (Figure 7).
These findings suggest direct effects of the ‘prohormone’
despite its reported low affinity for the VDR. In the whole
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Figure 1 | Reverse transcription-PCR of 1aOHase mRNA from
cultured bPTC. Total RNA was isolated from confluent cultures of
bPTC, and reverse transcription-PCR was performed using primers
specific for bovine 1aOHase (CYP27B1) as described in Materials and
Methods.
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Figure 2 | 1aOHase activity in cultured bPTC. Confluent cultures of
bPTC were incubated with the specified concentration of 25(OH)D3
for 24 h. Medium was analyzed for 1-hydroxylated metabolites by RIA
(IDS Inc., Fountain Hills, AZ, USA). Data are expressed as mean7s.d.
(n¼ 3). *Pp0.001 vs substrate control.
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Figure 3 | Suppression of PTH secretion by 25(OH)D3 and
1,25(OH)2D3. Confluent cultures of bPTC were incubated with the
specified concentrations of 25(OH)D3 or 1,25(OH)2D3 for 72 h with
daily media changes. The cells were placed in fresh medium for
3 h and PTH in the medium was measured by enzyme-linked
immunosorbent assay (Immutopics). Data are from two independent
experiments and are expressed as mean7s.d. (n¼ 12). *Po0.05
vs ethanol control; **Po0.01 vs ethanol control.
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cell, however, additional factors may influence the ability of a
ligand to interact with an intracellular receptor such as
intracellular binding proteins,17 metabolizing enzymes, etc.
We therefore measured the VDR binding of 25(OH)D3 using
a whole cell assay.18,19 As shown in Figure 8, 25(OH)D3
displays a VDR affinity that is several hundred times lower
than that of 1,25(OH)2D3. In addition, intermediate concen-
trations of 25(OH)D3 reproducibly produced an increase
in binding of the [3H]1,25(OH)2D3 ligand, suggesting that
it may compete for additional 1,25(OH)2D3 binding sites
within the cell allowing more 1,25(OH)2D3 binding to the
VDR. The nature of these other sites is under investigation.
Nevertheless, the lower VDR affinity of 25(OH)D3 is
quantitatively similar to its lower activity in suppre-
ssing PTH.
DISCUSSION
Parathyroid glands express the major enzymes involved in the
activation and degradation of vitamin D metabolites.15,16,20,21
These findings suggest the existence of an autocrine system
for vitamin D in the control of parathyroid gland function.
Circulating vitamin D3 or 25(OH)D3 could be converted to
the most active metabolite, 1,25(OH)2D3, within parathyroid
glands. In the present study, we have demonstrated that
cultured bPTC continue to express 1aOHase mRNA and acti-
vity, and are capable of converting 25(OH)D3 to 1,25(OH)2
D3. Thus, cultured bPTC provide a convenient model to
examine autocrine vitamin D effects.
The demonstration of 1,25(OH)2D3 production by
parathyroid cells has been difficult owing to its very rapid
conversion to more polar metabolites.16 Previous attempts
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Figure 4 | Reduction of PTH mRNA secretion by 25(OH)D3 and
1,25(OH)2D3. Confluent cultures of bPTC were incubated with the
specified concentrations of 25(OH)D3 or 1,25(OH)2D3 for 72 h with
daily media changes. PTH mRNA and 18S rRNA were measured by
Northern blot analysis. Data are expressed as mean7s.d. (n¼ 3).
*Po0.05 vs ethanol control; **Po0.01 vs ethanol control.
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Figure 5 | Inhibition of parathyroid cell 1aOHase by clotrimazole.
Confluent bPTC were incubated with 100 nM 25(OH)D3 and increasing
concentrations of clotrimazole for 24 h. Medium was analyzed for
1-hydroxylated metabolites by RIA. Data are expressed as
mean7s.d. (n¼ 3). Po0.001 vs no clotrimazole control.
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Figure 6 | Effect of clotrimazole on suppression of PTH mRNA by
25(OH)D3. Confluent bPTC were incubated with ethanol vehicle or
100 nM 25(OH)D3 in the absence or presence of 1 mM clotrimazole
(clot) for 72 h with daily media changes. Total RNA was isolated and
analyzed for PTH mRNA and 18S rRNA by Northern blot analysis. Data
are from two independent experiments and are expressed as
mean7s.d. (n¼ 6 total). *Po0.001 vs no 25(OH)D3 control.
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Figure 7 | Effect of clotrimazole on induction of 24-OHase mRNA.
Confluent bPTC were incubated with ethanol vehicle or 100 nM
25(OH)D3 in the absence or presence of 1 mM clotrimazole (clot) for
72 h with daily media changes. Total RNA was isolated and 24-OHase
mRNA and 18S rRNA were measured by Northern blot analysis. Data
are expressed as mean7s.d. (n¼ 3). *Po0.001 vs no 25(OH)D3
control.
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to measure synthesis of 1,25(OH)2D3 from high specific
activity [3H]25(OH)D3 or from high concentrations of
radioinert 25(OH)D3 by radioreceptor assay were not
successful (unpublished data). However, we were able to
detect 1-hydroxylated metabolite production by parathyroid
cells using an RIA that recognizes the 1a-hydroxyl moiety.
The high specificity for detection of 1,25(OH)2D3 over
25(OH)D3 (41000-fold) allowed the use of high substrate
concentrations in these studies. As in the previous studies, we
were unable to detect a 1,25(OH)2D3 peak by high-pressure
liquid chromatography using the RIA owing to rapid
metabolism (data not shown). On the other hand, because
it measures all 1-hydroxylated metabolites, the RIA provides
an accurate measure of 1aOHase activity. In addition, it is
important to note that although 1,25(OH)2D3 is the most
active metabolite of 25(OH)D3, side-chain metabolites of
1,25(OH)2D3 retain significant activity and could potentially
contribute to the suppression of PTH.22–24
The production of 1-hydroxylated metabolites by para-
thyroid cells was detectable with the RIA at substrate
concentrations above 10 nM. The minimum circulating
concentration of 25(OH)D3 required to maintain PTH at
normal levels is roughly 100 nM (40 ng/ml). Thus, 1,25(OH)2
D3 production in bPTC occurs at concentrations of
25(OH)D3 that are similar to its in vivo levels. However,
the delivery and cellular uptake may be different between the
in vitro and in vivo situations. Our bPTC were cultured in the
absence of serum and therefore the medium lacks the serum
vitamin D binding protein, which has a high affinity for
25(OH)D3. To keep the hydrophobic 25(OH)D3 in solution
and minimize adherence to the plastic culture dish, the
medium contained bovine serum albumin (1 mg/ml), which
has a lower affinity for vitamin D compounds. Thus, the
proportion of free 25(OH)D3 in our cultures was higher than
that in vivo and may have favored uptake by the parathyroid
cells. On the other hand, the parathyroid glands express the
cell surface receptor megalin (gp330/LRP2),15,25 which has
been shown to be critical for the proximal tubular uptake
of diastolic blood pressure-bound 25(OH)D3.
26–28 Whether
megalin plays a similar role in parathyroid cells is under
investigation.
Suppression of PTH occurred at concentrations of
25(OH)D3 at which 1-hydroxylation was detected, suggesting
an autocrine role for 1,25(OH)2D3. Surprisingly, inhibition
of the 1aOHase with clotrimazole did not prevent PTH
suppression by 25(OH)D3. These findings implicate a direct
action of 25(OH)D3, presumably through VDR binding, on
PTH gene transcription. This is supported by the observation
that 25(OH)D3 could induce the 24-hydroxylase (24-OHase)
mRNA in the presence of clotrimazole. In fact, induction of
this gene was enhanced by the inhibitor. This is likely
attributable to the inhibition of 24-OHase activity by
clotrimazole. It is known that increases in 24-OHase are
relatively short-lived and that once the inducing vitamin D
metabolite is degraded, 24-OHase mRNA rapidly returns to
basal levels. Clotrimazole, then, would slow 25(OH)D3
metabolism, allowing a more sustained effect on 24-OHase
gene transcription, as observed in Figure 7. The lack of
potentiation of PTH mRNA is likely owing to the more sus-
tained effect of vitamin D compounds on PTH gene trans-
cription. For example, we observed that a single injection
of the rapidly cleared analog 22-oxa-1,25(OH)2D3 could
suppress PTH for up to 3 days despite its clearance within
4 h.29 Thus, the potentiating effect of blocking cata-
bolism of active vitamin D compounds appears to be
gene-specific.
Clotrimazole is a general inhibitor of cytochrome P450s.
Specific inhibitors for the 1aOHase are not available.
Clotrimazole competes for the substrate binding, as does
the more commonly used inhibitor ketoconazole. However,
in a previous study, we found that ketoconazole itself could
suppress PTH secretion and mRNA levels, possibly by affect-
ing cytosolic calcium,30 which is known to regulate PTH
mRNA.31 Clotrimazole did not affect PTH at the concentra-
tions required to inhibit the 1aOHase.
The finding that 25(OH)D3 can directly suppress PTH is
similar to our recent report32 that the vitamin D prodrug,
1a(OH)D2, which lacks the 25-hydroxyl group, could
suppress PTH even when its conversion to 1,25(OH)2D2
was blocked with ketoconazole. Like 25(OH)D3, 1a(OH)D2
has a very low affinity for the VDR. How these compounds
exert their direct effects is not clear. In the present study, we
measured the VDR affinity of 25(OH)D3 using an intact cell
assay and found that 25(OH)D3 has several hundred times
lower affinity than 1,25(OH)2D3. This is similar to the
relative activities of the two compounds in suppressing
PTH in bPTC. It is important to note that although the
VDR affinity and PTH-suppressing activity of 25(OH)D3 are
several hundred-fold lower than that of 1,25(OH)2D3, the
circulating concentration of 25(OH)D3 is nearly 1000 times
higher. Thus, it can be argued that under physiologic
Competitor (nM)
25(OH)D3
1,25(OH)2D3[
3 H
]1,
25
(O
H)
2D
3 
bo
un
d 
(d.
p.m
.)
0 0.25 0.50 1 2 4 8 16 32 64 128 256 512 1024
6000
5000
4000
3000
2000
1000
Figure 8 | Competitive VDR binding of 25(OH)D3 and
1,25(OH)2D3. Confluent bPTC were incubated with [
3H]1,25(OH)2D3
(0.5 nM) with increasing concentrations of radioinert 1,25(OH)2D3 or
25(OH)D3 for 2 h. The cells were chilled, washed rapidly, and
sonicated. The sonicates were treated with charcoal/dextran and
centrifuged to remove unbound ligand, and the supernatant
containing the VDR was counted for tritium (see Materials
and Methods for details). Data are expressed as mean7s.d.
(n¼ 3).
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conditions, endogenous 25(OH)D3 contributes to the overall
control of parathyroid gland function by metabolites of
vitamin D.
The intact cell binding assay also revealed possibly an
additional, non-VDR binding site for 1,25(OH)2D3. Inter-
mediate concentrations of 25(OH)D3 produced a reprodu-
cible increase in [3H]1,25(OH)2D3 binding (Figure 8),
suggesting that 25(OH)D3 releases 1,25(OH)2D3 from an as
yet unknown site for binding to the VDR. We have not
observed this with other vitamin D compounds in previous
studies with intact parathyroid cells.23,24 The nature of this
binding site and its potential role in modulating vitamin D
action in parathyroid cells is under investigation.
Consistent with the notion that 25(OH)D3 can act directly
on the parathyroid glands to repress PTH synthesis are the
observations that PTH levels in subjects with mild to
moderate vitamin D deficiency correlate inversely with serum
25(OH)D3, but not with 1,25(OH)2D3.
8–13 One explanation
is that as the 25(OH)D3 levels fall, renal production of
1,25(OH)2D3 is reduced, leading to decreased calcium
absorption and a resulting elevation in PTH. The higher
PTH induces 1aOHase expression, which compensates for
the low substrate, normalizing 1,25(OH)2D3 and calcium
absorption. Thus, PTH is increased as 25(OH)D3 levels fall,
but 1,25(OH)2D3 and calcium remain in the normal range.
Although this compensatory model is consistent with
our understanding of calcium homeostasis and regulation
of vitamin D metabolism, it does not exclude the possibility
that increased PTH synthesis is a direct response of the
parathyroid glands to the reduced 25(OH)D3. The results of
the present studies indicate that indeed 25(OH)D3 can
suppress PTH synthesis by parathyroid cells and that
activation to 1,25(OH)2D3 is apparently not required,
suggesting a direct interaction of 25(OH)D3 with the VDR.
MATERIALS AND METHODS
Preparation of dispersed bPTC
Dispersed bPTC were prepared as previously described.16 Briefly,
bovine parathyroid glands (obtained from MBH Enterprises,
Tampa, FL, USA) were trimmed of extraneous fatty tissue,
sliced to 0.5 mm thickness with a tissue slicer (Stadie Riggs;
Thomas Scientific, Swedesboro, NJ, USA), and placed in a mixture
of Dulbecco’s modified Eagle’s medium (DME):Ham’s F-12 medium
50:50 containing 0.5 mM calcium and collagenase (3000 U/ml
of collagenase XI-S; Sigma, St Louis, MO, USA). The suspension
(10 ml media per gram of tissue) was agitated in a shaking
water bath at 371C for 90 min. Periodic passage of the mixture
through the tip of a 10 ml pipette assisted in the disaggregation. The
digested tissue was washed three times with serum-free culture
medium containing DME:Ham’s F-12 (50:50), 1 mM CaCl2, 15 mM
Hepes, 100 IU/ml penicillin, 100 mg/ml streptomycin, 5 mg/ml
insulin, 5 mg/ml holo-transferrin, 2 mM glutamine, 1% non-essential
amino acids, and 0.1% bovine serum albumin (fraction V).
Dispersed cells were plated in 12- or 24-well culture plates at
0.32 or 0.16 106/well, respectively, in the above medium contain-
ing 4% newborn calf serum. After 24 h, the medium was replaced
with serum-free medium. Medium was changed every 2–3 days of
culture.
Regulation of PTH release by bPTC
Primary cultures of bPTC were grown to confluency in serum-free
medium as previously described,16 and then treated for 72 h with
0.01, 0.1, 1.0, 10, 100, or 1000 nM 25(OH)D3 or 1,25(OH)2D3, with
daily changes of medium. The cells were then changed into fresh
medium and the amount of PTH secreted during a 4-h incubation
was determined using an intact bovine PTH ELISA kit (Immutopics,
San Capistrano, CA, USA).
Reverse transcription-PCR of 25-hydroxyvitamin D
1a-hydroxylase (CYP27B1) in bPTC
Total RNA was isolated from confluent cultures of bPTC using
RNAzol Bee (Tel-Test Inc., Friendswood, TX, USA) as directed by
the manufacturer. Reverse transcription of the RNA was carried out
using oligo-dT primer and reverse transcriptase (Superscript II,
Invitrogen, Carlsbad, CA, USA) as directed. PCR was performed
using specific primers for bovine CYP27B1 (forward: 50-GGAACCA
GTCTGAGAAGTC-30 and reverse: 50-CAAAGTGGATCAAGATCT
G-30) from exons 5 and 9, respectively.
Northern blot analysis of PTH and 24-hydroxylase mRNA
Total RNA was harvested from the cells using RNAzol Bee, resolved
on 1.2% agarose/formaldehyde gels, and transferred to a nylon
membrane (Zeta-Probe, Bio-Rad, Hercules, CA, USA). PTH mRNA
and 18S rRNA were measured by hybridizing the membranes
with riboprobes described previously.33 24-Hydroxylase mRNA
was quantified by hybridizing with a riboprobe against the rat
24-hydroxylase cDNA described previously.34 Band intensities were
quantified using a phosphorimager (Amersham Storm 840, GE
Healthcare, Piscataway, NJ, USA) with background subtraction. The
data are expressed as the ratio of PTH mRNA or 24-hydroxylse
mRNA to 18S rRNA.
Metabolism
To determine the rate of 1-hydroxylation of 25(OH)D3, confluent
monolayers of bPTC were incubated with various concentrations of
25(OH)D3 for 24 h. Medium was collected and analyzed for
1-hydroxylated metabolites using the 1,25(OH)2D3 RIA from
Immunodiagnostics Systems Inc. (Fountain Hills, AZ, USA).
Samples of medium containing the same concentrations of
25(OH)D3 were incubated under identical conditions but without
cells to control for crossreactivity of 25(OH)D3 in the assay. The
samples (500 ml) were delipidated and immunoextracted using an
immobilized monoclonal antibody to the 1a-hydroxyl group. After
washing the cartridges, the 1-hydroxylated metabolites were eluted,
dried under nitrogen, and reconstituted in assay buffer. The
immunoextracted samples were mixed with primary antibody
overnight at 41C and then 125I-1,25(OH)2D3 was added and the
incubation continued for 2 h at room temperature. Bound and free
label was separated using immobilized second antibody. Bound
radioactivity, quantified with a gamma counter, was inversely
proportional to the 1-hydroxylated metabolite in the samples.
VDR binding assay
Confluent parathyroid cells were incubated for 2 h with 0.5 nM
1,25(OH)2-(26,27-
3H)D3 and the indicated concentration of radio-
inert 1,25(OH)2D3 or 25(OH)D3 in serum-free medium containing
0.1 mg/ml bovine serum albumin. The medium was aspirated and
the cells were washed once with phosphate-buffered saline contain-
ing 1 mg/ml bovine serum albumin and then twice more with ice-
cold phosphate-buffered saline. The cells were sonicated in cold
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TEDK buffer (10 mM Tris-HCl, pH 7.4, 1.5 mM ethylenediaminete-
traacetic acid, 5 mM dithiothreitol, 300 mM KCl). The sonicate was
mixed with 200 ml of charcoal/dextran, kept on ice for 15 min, and
centrifuged at 1000 g for 15 min. The supernatants containing the
VDR were mixed with 4 ml of ScintiVerse BD (Fisher Scientific,
Pittsburgh, PA, USA) and the tritium was quantified by scintillation
counting.
Statistics
Data were analyzed by analysis of variance using the GraphPad
software package.
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